Travere Therapeutics, Inc. (TVTX): Insider Trading, Congress Trades & Research | Tormere

TVTX

$56.93+0.14%website ↗⬇ financials (.py)

Travere Therapeutics, Inc.

Market Cap

$5.3B

Live price × shares (2026-09-17)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.11

60mo monthly vs SPY

P/E (TTM)

N/M

Price / TTM net income

P/S (TTM)

9.0

Price / TTM revenue

P/B

215.9

Price / stockholders equity

EV/EBITDA

226.9

TTM

Price Chart

Loading…

Signals

Insider Velocity

Market & Alt Data

News

15

recent articles

Analyst Consensus

Strong Buy

21 analysts

Velocity Score

16.89x

Sell Rate (90d)

11761.84/mo

Sell Baseline

2050.01/mo

Unique Sellers (90d)

9

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-09-17	2026-09-17	Dube Eric M	Director & CHIEF EXECUTIVE OFFICER	Sale	108.5K	$64.61	$7.01M	432.9K	View
2026-09-17	2026-09-17	Heerma Peter	EVP, CHIEF COMMERCIAL OFFICER	Sale	8,282	$65.07	$539K	117.1K	View
2026-09-16	2026-09-17	Heerma Peter	EVP, CHIEF COMMERCIAL OFFICER	Sale	172.7K	$63.43	$10.96M	117.1K	View
2026-09-16	2026-09-17	ROTE WILLIAM E.	Chief Research Officer	Sale	112.8K	$63.33	$7.15M	98.2K	View
2026-09-16	2026-09-17	Dube Eric M	Director & CHIEF EXECUTIVE OFFICER	Sale	195.8K	$63.45	$12.43M	432.9K	View

1–5 of 53

1 / 11

Reporting Insiders

Recent News

Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

Yahoo · 2026-10-02

Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89

Benzinga · 2026-09-24

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

Yahoo · 2026-09-23

Travere Therapeutics (TVTX) Sets CEO Handover For December 2026

Yahoo · 2026-09-23

SBIO: Big Pharma Needs What This Fund Owns

SeekingAlpha · 2026-09-22

Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today

Yahoo · 2026-09-22

Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

Benzinga · 2026-09-22

HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

Benzinga · 2026-09-22

Travere Therapeutics Announces Planned Chief Executive Officer Transition

Yahoo · 2026-09-21

Travere Therapeutics Appoints Bradley L. Campbell President, CEO, Effective Dec. 1, Succeeding Eric Dube

Benzinga · 2026-09-21

Travere Therapeutics (NASDAQ:TVTX) Passes Minervini Trend Template With High-Growth Momentum

ChartMill · 2026-09-21

Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum

Yahoo · 2026-09-17

Travere Therapeutics' Outlook Brightens As Turnaround Looms

Yahoo Finance · 2026-09-08

IBD Stock Of The Day, Travere Therapeutics, Tests Another Breakout. Can The Stock Get Any 'Sweeter?'

Yahoo Finance · 2026-08-21

Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?

Yahoo Finance · 2026-06-13

Informational purposes only, not investment advice.

Recent Insider Activity (Form 4) — Last 5

Date	Insider	Type	Shares	Value
2026-09-17	Dube Eric M	S	6,802	$441,795.34
2026-09-17	Heerma Peter	S	8,282	$538,917.19
2026-09-17	Dube Eric M	S	101,691	$7M
2026-09-16	Heerma Peter	S	93,604	$6M
2026-09-16	Heerma Peter	S	79,113	$5M